Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Generic medicines news


From To
Pharma giant withdraws challenge to generic HIV anti-retroviral drug

Gilead has dropped its appeal against the High Court’s refusal to grant an injunction against generic manufacturers.

21 December 2017
Irish Times
This Company Is About to Flood the US With Cheap HIV Drugs

U.S. patents on key components for some important HIV therapies are poised to expire starting in December and Laurus Labs Ltd. -- the Hyderabad, India-based company which owns the facility -- is gearing up to cash in.

04 December 2017
Gilead loss of generic HIV drug battle a boost for gay community

09 November 2017
The Irish Times
A year of generic PrEP could recoup its own cost within five years if effectiveness is high, Public Health England model finds

A cost-effectiveness model developed by Public Health England finds that just one year’s worth of pre-exposure prophylaxis (PrEP), given to gay men during a period

23 October 2017
Gus Cairns
Gilead Continues To Block Ireland From Sourcing Generic Truvada

Gilead Sciences, the company that supplies Ireland with the drug Truvada, will have a full court hearing in mid-October to determine whether the Irish Health and Safety Executive (HSE) can source a generic analogue of the drug from the pharmaceutical giant’s competitors. In July, GCN reported that Gilead was taking legal action to stop the HSE from securing generic drug from Actavis and Mylan, the company’s competitors, for the purposes of HIV prevention as PrEP.

16 October 2017
Gay Community News
Brand Name Vs Generic Drugs: The Fight Continues

Many patients and practitioners are looking to generics to ease the pressure of skyrocketing antiretroviral (ART) drug prices, but according to Rochelle P Walensky, MD, Professor of Medicine at Harvard Medical School, they shouldn’t hold their breath.

10 October 2017
MD Mag
New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price

A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries (LMICs) at around US$75 per person, per year.

22 September 2017
Generic PrEP in France and Scotland challenges access across the UK

The issue of drug procurement and pricing is complex but it is difficult to see how different patents should apply within Europe, and especially not within the UK.

08 September 2017
HIV i-Base
Did HIV Pharma “Pay to Delay” Generic Truvada?

AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.

04 September 2017
No evidence of reduced efficacy or increased side-effects when patients switch to generic drugs, comparison study finds

An analysis of 440 people switched to generic antiretroviral drugs at an Italian clinic and a matched cohort of patients who remained on their branded medication has

24 August 2017
Roger Pebody

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.